+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pharmacyclics llc - logo

Pharmacyclics LLC focuses on developing novel therapies for the treatment of cancer and immune-mediated diseases in the United States. The company markets IMBRUVICA, a single-agent therapy used for the treatment of patients with chronic lymphocytic leukemia, mantle cell lymphoma and waldenström's macroglobulinemia. It also has several product candidates in clinical development. The company was founded in 1991 and is headquartered in Sunnyvale, California.

From
From
From
Diffuse Large B Cell Lymphoma - Pipeline Insight, 2021 - Product Thumbnail Image

Diffuse Large B Cell Lymphoma - Pipeline Insight, 2021

  • Clinical Trials
  • June 2021
  • 60 pages
From
MALT Lymphoma - Pipeline Insight, 2020 - Product Thumbnail Image

MALT Lymphoma - Pipeline Insight, 2020

  • Clinical Trials
  • February 2020
  • 106 pages
From
Mantle Cell Lymphoma - Pipeline Insight, 2020 - Product Thumbnail Image

Mantle Cell Lymphoma - Pipeline Insight, 2020

  • Clinical Trials
  • February 2020
  • 106 pages
From
From
From
From
From
From
Cancer Stem Cell Therapies Market, 2017-2030 - Product Thumbnail Image

Cancer Stem Cell Therapies Market, 2017-2030

  • Report
  • December 2017
  • 270 Pages
From
HDAC Inhibitors Market, 2016 - 2026 - Product Thumbnail Image

HDAC Inhibitors Market, 2016 - 2026

  • Report
  • August 2016
  • 233 Pages
From
Factor VIIa Inhibitor - Pipeline Insight, 2020 - Product Thumbnail Image

Factor VIIa Inhibitor - Pipeline Insight, 2020

  • Clinical Trials
  • July 2020
  • 60 pages
From
Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight - Product Thumbnail Image

Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight

  • Drug Pipelines
  • November 2014
  • 573 Pages
From
From
Loading Indicator
adroll